149 related articles for article (PubMed ID: 34598309)
1. Incorporating genetic and clinical data into the prediction of thromboembolism risk in patients with lymphoma.
Bastos-Oreiro M; Ortiz J; Pradillo V; Salas E; Marínez-Laperche C; Muñoz A; Buño I; Diéz-Martin JL; Soria JM; Pascual Izquierdo C
Cancer Med; 2021 Nov; 10(21):7585-7592. PubMed ID: 34598309
[TBL] [Abstract][Full Text] [Related]
2. Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer.
Muñoz Martín AJ; Ortega I; Font C; Pachón V; Castellón V; Martínez-Marín V; Salgado M; Martínez E; Calzas J; Rupérez A; Souto JC; Martín M; Salas E; Soria JM
Br J Cancer; 2018 Apr; 118(8):1056-1061. PubMed ID: 29588512
[TBL] [Abstract][Full Text] [Related]
3. The Incidence of Venous Thromboembolism and Impact on Survival in Hodgkin Lymphoma.
Kirkizlar O; Alp Kirkizlar T; Umit EG; Asker I; Baysal M; Bas V; Gulsaran SK; Demirci U; Demir AM
Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):542-547. PubMed ID: 32245743
[TBL] [Abstract][Full Text] [Related]
4. PO-04 - A new genetic risk score for predicting venous thromboembolic events in cancer patients receiving chemotherapy.
Martín AJ; Ziyatdinov A; Rubio VC; Olmos VP; Huerta BM; Rodríguez JC; Fernández MS; de Castro EM; Caro RL; Fernández JM
Thromb Res; 2016 Apr; 140 Suppl 1():S177-8. PubMed ID: 27161691
[TBL] [Abstract][Full Text] [Related]
5. A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts.
Muñoz A; Ay C; Grilz E; López S; Font C; Pachón V; Castellón V; Martínez-Marín V; Salgado M; Martínez E; Calzas J; Ortega L; Rupérez A; Salas E; Pabinger I; Soria JM
J Clin Oncol; 2023 Jun; 41(16):2911-2925. PubMed ID: 36730884
[TBL] [Abstract][Full Text] [Related]
6. Multilocus genetic risk scores for venous thromboembolism risk assessment.
Soria JM; Morange PE; Vila J; Souto JC; Moyano M; Trégouët DA; Mateo J; Saut N; Salas E; Elosua R
J Am Heart Assoc; 2014 Oct; 3(5):e001060. PubMed ID: 25341889
[TBL] [Abstract][Full Text] [Related]
7. The Application of the ThroLy Risk Assessment Model to Predict Venous Thromboembolism in Patients with Diffuse Large B-Cell Lymphoma.
Abdel-Razeq H; Ma'koseh M; Mansour A; Bater R; Amarin R; Abufara A; Halahleh K; Manassra M; Alrwashdeh M; Almomani M; Zmaily M
Clin Appl Thromb Hemost; 2021; 27():10760296211045908. PubMed ID: 34590497
[TBL] [Abstract][Full Text] [Related]
8. Prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies: validation of the Khorana Risk Score.
Rupa-Matysek J; Gil L; Kaźmierczak M; Barańska M; Komarnicki M
Med Oncol; 2017 Dec; 35(1):5. PubMed ID: 29209847
[TBL] [Abstract][Full Text] [Related]
9. Comparison between the Khorana prediction score and Caprini risk assessment models for assessing the risk of venous thromboembolism in hospitalized patients with cancer: a retrospective case control study.
Hu Y; Li X; Zhou H; Lin P; Zhang J; Huang D; Qi M; Tang Y; Yi Q; Liang Z; Wang M
Interact Cardiovasc Thorac Surg; 2020 Oct; 31(4):454-460. PubMed ID: 32910201
[TBL] [Abstract][Full Text] [Related]
10. High plasma levels of soluble P-Selectin and Factor VIII predict venous thromboembolism in non-small cell lung cancer patients: The Thrombo-Nsclc risk score.
Castellón Rubio VE; Segura PP; Muñoz A; Farré AL; Ruiz LC; Lorente JA
Thromb Res; 2020 Dec; 196():349-354. PubMed ID: 32977135
[TBL] [Abstract][Full Text] [Related]
11. A modified Khorana score as a risk assessment tool for predicting venous thromboembolism in newly diagnosed advanced lung cancer.
Li S; Gao P; Qiu J; He X; Mao Y
J Thromb Thrombolysis; 2021 Oct; 52(3):898-903. PubMed ID: 33599857
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the ThroLy score for the prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies in clinical practice.
Rupa-Matysek J; Brzeźniakiewicz-Janus K; Gil L; Krasiński Z; Komarnicki M
Cancer Med; 2018 Jul; 7(7):2868-2875. PubMed ID: 29761831
[TBL] [Abstract][Full Text] [Related]
13. Venous Thrombosis Risk after Cast Immobilization of the Lower Extremity: Derivation and Validation of a Clinical Prediction Score, L-TRiP(cast), in Three Population-Based Case-Control Studies.
Nemeth B; van Adrichem RA; van Hylckama Vlieg A; Bucciarelli P; Martinelli I; Baglin T; Rosendaal FR; le Cessie S; Cannegieter SC
PLoS Med; 2015 Nov; 12(11):e1001899; discussion e1001899. PubMed ID: 26554832
[TBL] [Abstract][Full Text] [Related]
14. Utilization of the Caprini score in conjunction with thrombodynamic testing reduces the number of unpredicted postoperative venous thromboembolism events in patients with colorectal cancer.
Lobastov K; Dementieva G; Soshitova N; Bargandzhiya A; Barinov V; Laberko L; Rodoman G
J Vasc Surg Venous Lymphat Disord; 2020 Jan; 8(1):31-41. PubMed ID: 31495765
[TBL] [Abstract][Full Text] [Related]
15. The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With Chemotherapy.
Ramos JD; Casey MF; Bamias A; De Giorgi U; Bellmunt J; Harshman LC; Ladoire S; Wong YN; Alva AS; Rosenberg JE; Galsky MD; Yu EY;
Clin Appl Thromb Hemost; 2017 Oct; 23(7):755-760. PubMed ID: 27637910
[TBL] [Abstract][Full Text] [Related]
16. Assessing the risk of venous thromboembolism in patients with haematological cancers using three prediction models.
El-Sayed HA; Othman M; Azzam H; Bucciol R; Ebrahim MA; El-Agdar MAMA; Tera Y; Sakr DH; Ghoneim HR; Selim TE
J Cancer Res Clin Oncol; 2023 Dec; 149(20):17771-17780. PubMed ID: 37935936
[TBL] [Abstract][Full Text] [Related]
17. Risk of venous thromboembolism in patients with non-Hodgkin lymphoma surviving blood or marrow transplantation.
Gangaraju R; Chen Y; Hageman L; Wu J; Francisco L; Kung M; Ness E; Parman M; Weisdorf DJ; Forman SJ; Arora M; Armenian SH; Bhatia S
Cancer; 2019 Dec; 125(24):4498-4508. PubMed ID: 31469420
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of application of risk assessment models (Padua Prediction Score and Improve Bleeding Score) on venous thromboembolism, major hemorrhage and health expenditure associated with pharmacologic VTE prophylaxis: a "real life" prospective and retrospective observational study on patients hospitalized in a Single Internal Medicine Unit (the STIME study).
Depietri L; Marietta M; Scarlini S; Marcacci M; Corradini E; Pietrangelo A; Ventura P
Intern Emerg Med; 2018 Jun; 13(4):527-534. PubMed ID: 29502330
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of risk factors and assessment models for predicting venous thromboembolism in lung cancer patients.
Rupa-Matysek J; Lembicz M; Rogowska EK; Gil L; Komarnicki M; Batura-Gabryel H
Med Oncol; 2018 Apr; 35(5):63. PubMed ID: 29616356
[TBL] [Abstract][Full Text] [Related]
20. Assessing the risk of venous thromboembolism (VTE) in ambulatory patients with cancer: Rationale and implementation of a pharmacist-led VTE risk assessment program in an ambulatory cancer centre.
Pelletier R
J Oncol Pharm Pract; 2021 Jun; 27(4):911-918. PubMed ID: 33757321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
